Mayo Clinic researchers unveiled a predictive model that estimates Alzheimer’s risk years before clinical symptoms using decades of clinic data; the model appears to stratify individuals for surveillance and early intervention trials. Separately, University of Chicago scientists introduced Ultra‑Mild Bisulfite Sequencing (UMBS‑seq), a gentler DNA methylation method that preserves DNA integrity while enabling high‑accuracy cancer methylome profiling. The Mayo model, published in The Lancet Neurology, leverages longitudinal clinical and biomarker data to produce individualized risk estimates, potentially shifting enrollment into prevention trials. UMBS‑seq reduces DNA degradation inherent to classical bisulfite conversion and may expand methylation‑based liquid biopsy applications. Together these advances lower barriers for earlier detection and molecular stratification across neurodegeneration and oncology pipelines, prompting investors and diagnostics developers to reassess analytic tradeoffs and clinical utility thresholds.